Search | Clinical Trials Finder

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: La Mesa, California • Oklahoma City, Oklahoma • Fort Worth, Texas

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BIIB019 (Daclizumab High Yield Process), Interferon beta-1a Placebo, Interferon beta-1a, Daclizumab High Yield Process Placebo; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 46
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Immune Mediated Necrotizing Myopathy
Interventions: zilucoplan, Placebo; Drug · Other
Lead sponsor: Ra Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 11 more

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Influenza
Interventions: MK-1406, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 123
States / cities: Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 107 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
Interventions: Tozorakimab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 16
States / cities: Sheffield, Alabama • Newport Beach, California • Newark, Delaware + 13 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: LY3540378, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 22
States / cities: Tucson, Arizona • Covina, California • Northridge, California + 18 more

Conditions: Multiple Sclerosis, Relapsing Forms
Interventions: MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Acthar, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Asthma
Interventions: dupilumab, Matching Placebo, ICS/LABA; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 51
States / cities: Bakersfield, California • La Jolla, California • Lancaster, California + 47 more

Conditions: HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions: Arm A: Poly-ICLC, Arm B: Normal Saline; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence
Interventions: Reslizumab, Placebo, Non-Oral Corticosteroid (non-OCS) Asthma Medication, Oral Corticosteroid (OCS); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Bakersfield, California • Long Beach, California • Clermont, Florida + 21 more

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Obesity
Interventions: Ribupatide, Semaglutide, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 28
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more

Conditions: Dengue Fever
Interventions: TAK-003, Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more

Conditions: IgG4 Related Disease
Interventions: Obexelimab, Placebo; Drug · Other
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Stanford, California • Naples, Florida • Atlanta, Georgia + 2 more

Conditions: Ulcerative Colitis
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 120
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 103 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more

Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more

Conditions: Asthma
Interventions: AMG 691, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Lake Forest, California • Aventura, Florida • Palmetto Bay, Florida + 12 more

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Tadalafil, Placebo, Saline load; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Activin ligand-trap biological therapy, Placebo, Normal Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypophosphatasia
Interventions: ALXN1850, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Indianapolis, Indiana • Garden City, New York • Durham, North Carolina + 2 more

Search by objective public record fields.

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

SAD and MAD Study of FTX-101 in Healthy Male Subjects

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Enhancement by Poly-ICLC During HIV-1 Infection

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa